GlassScriptPhysician profile
Dereck Davis
NPI 1174567580
$19,755.12
in general payments reported to CMS, 2019-2025
37 companies · $459 in 2025
The $459 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $726 · 2020: $203 · 2021: $72.15 · 2022: $8,297 · 2023: $8,942 · 2024: $1,057 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,800 · Food and Beverage: $2,405 · Travel and Lodging: $253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,800.00 |
| Food and Beverage | $2,404.56 |
| Travel and Lodging | $252.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $13,667.17 | 2022-2023 | |
| Sobi, INC | $2,693.92 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $522.66 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $376.02 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $288.61 | 2022-2024 | |
| Pfizer INC. | $281.87 | 2019-2025 | |
| National Marrow Donor Program | $214.51 | 2024 | |
| Agios Pharmaceuticals, INC. | $161.30 | 2023-2024 | Pyrukynd |
| Csl Behring | $131.73 | 2020-2024 | Hemgenix |
| Amgen INC. | $131.24 | 2019-2020 | |
| Y-Mabs Therapeutics, INC. | $114.02 | 2023 | Danyelza |
| Kite Pharma, INC. | $96.69 | 2022 | |
| Emmaus Medical, INC. | $88.36 | 2019-2025 | Endari |
| Servier Pharmaceuticals LLC | $87.38 | 2019-2020 | |
| Bioverativ Therapeutics INC. | $83.72 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $83.57 | 2024-2025 | Prevymis |
| Global Blood Therapeutics, INC. | $80.61 | 2020-2021 | |
| Mesoblast, INC. | $79.68 | 2025 | Ryoncil |
| Novo Nordisk INC | $79.05 | 2019-2024 | Esperoct |
| Rare Disease Therapeutics, INC. | $67.14 | 2024-2025 | Xromi, Purixan |
| Chiesi USA, INC. | $56.73 | 2024-2025 | Ferriprox |
| Puma Biotechnology, INC. | $54.87 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $42.80 | 2023-2024 | Koselugo, Ultomiris |
| Adaptive Biotechnologies Corporation | $35.37 | 2024 | Clonoseq |
| Grifols USA, LLC | $31.81 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.70 | 2020 | |
| Teleflex LLC | $25.75 | 2025 | Arrow |
| Hema Biologics, LLC | $23.48 | 2024 | Sevenfact |
| Celgene Corporation | $21.39 | 2025 | Breyanzi |
| Genetix Biotherapeutics INC | $18.83 | 2023 | |
| Uswm, LLC | $18.80 | 2024 | Iwilfin |
| Day One Biopharmaceuticals | $17.01 | 2025 | Ojemda |
| Bayer Healthcare Pharmaceuticals INC. | $16.95 | 2025 | |
| Adma Biomanufacturing LLC | $16.69 | 2020 | |
| Duchesnay USA Incorporated | $16.69 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dereck Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.